How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions

2.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

3.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

4.

Rohmer

J

,

Couteau-Chardon

A

,

Trichereau

J

, et al.

Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients

.

Am J Hematol

.

2020

;

95

(

11

):

1314

-

1323

.

5.

Metzgeroth

G

,

Steiner

L

,

Naumann

N

, et al.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort

.

Leukemia

.

2023

;

37

(

9

):

1860

-

1867

.

6.

Wang

SA

,

Orazi

A

,

Gotlib

J

, et al.

The International Consensus Classification of eosinophilic disorders and systemic mastocytosis

.

Am J Hematol

.

2023

;

98

(

8

):

1286

-

1306

.

7.

Valent

P

,

Klion

AD

,

Roufosse

F

, et al.

Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes

.

Allergy

.

2023

;

78

(

1

):

47

-

59

.

8.

Griesinger

F

,

Hennig

H

,

Hillmer

F

, et al.

A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia

.

Genes Chromosomes Cancer

.

2005

;

44

(

3

):

329

-

333

.

9.

Montenegro-Garreaud

X

,

Miranda

RN

,

Reynolds

A

, et al.

Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase

.

Hum Pathol

.

2017

;

65

:

147

-

156

.

10.

Gao

L

,

Xu

Y

,

Weng

LC

,

Tian

ZG

.

A rare cause of persistent leukocytosis with massive splenomegaly: myeloid neoplasm with BCR-PDGFRA rearrangement-case report and literature review

.

Medicine (Baltim)

.

2022

;

101

(

24

):

e29179

.

11.

Walz

C

,

Metzgeroth

G

,

Haferlach

C

, et al.

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene

.

Haematologica

.

2007

;

92

(

2

):

163

-

169

.

12.

Lahortiga

I

,

Akin

C

,

Cools

J

, et al.

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion

.

Haematologica

.

2008

;

93

(

1

):

49

-

56

.

13.

Gallagher

G

,

Horsman

DE

,

Tsang

P

,

Forrest

DL

.

Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders

.

Cancer Genet Cytogenet

.

2008

;

181

(

1

):

46

-

51

.

14.

Brown

LE

,

Zhang

D

,

Persons

DL

,

Yacoub

A

,

Ponnala

S

,

Cui

W

.

A 26-year-old female with systemic mastocytosis with associated myeloid neoplasm with eosinophilia and abnormalities of PDGFRB, t(4;5)(q21;q33)

.

Case Rep Hematol

.

2016

;

2016

:

4158567

.

15.

Wang

RC

,

Ward

D

,

Dunn

P

,

Chang

CC

.

Acute mast cell leukemia associated with t(4;5)(q21;q33)

.

Hum Pathol

.

2017

;

67

:

198

-

204

.

16.

Li

Y

,

Jing

Y

,

Wan

H

,

Liu

D

.

Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor β: a case report

.

Medicine (Baltim)

.

2021

;

100

(

8

):

e24707

.

17.

Gerds

AT

,

Gotlib

J

,

Bose

P

, et al.

Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021, NCCN clinical practice guidelines in oncology

.

J Natl Compr Canc Netw

.

2020

;

18

(

9

):

1248

-

1269

.

18.

Gotlib

J

.

Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms

.

Hematology Am Soc Hematol Educ Program

.

2022

;

2022

(

1

):

34

-

46

.

19.

Metzgeroth

G

,

Schwaab

J

,

Gosenca

D

, et al.

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

.

Leukemia

.

2013

;

27

(

11

):

2254

-

2256

.

20.

Cools

J

,

DeAngelo

DJ

,

Gotlib

J

, et al.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

.

N Engl J Med

.

2003

;

348

(

13

):

1201

-

1214

.

21.

Griffin

JH

,

Leung

J

,

Bruner

RJ

,

Caligiuri

MA

,

Briesewitz

R

.

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

.

Proc Natl Acad Sci U S A

.

2003

;

100

(

13

):

7830

-

7835

.

22.

Pardanani

A

,

Ketterling

RP

,

Brockman

SR

, et al.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

.

Blood

.

2003

;

102

(

9

):

3093

-

3096

.

23.

Score

J

,

Walz

C

,

Jovanovic

JV

, et al.

Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions

.

Leukemia

.

2009

;

23

(

2

):

332

-

339

.

24.

Olsson-Arvidsson

L

,

Norberg

A

,

Sjögren

H

,

Johansson

B

.

Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis

.

Br J Haematol

.

2020

;

188

(

5

):

e76

-

e79

.

25.

Pongdee

T

,

Berry

A

,

Wetzler

L

, et al.

False-negative testing for FIP1L1::PDGFRA by fluorescence in situ hybridization is a frequent cause of diagnostic delay

.

Acta Haematol

.

2023

;

146

(

4

):

316

-

321

.

26.

Reiter

A

,

Grimwade

D

,

Cross

NC

.

Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders

.

Haematologica

.

2007

;

92

(

9

):

1153

-

1158

.

27.

Baer

C

,

Muehlbacher

V

,

Kern

W

,

Haferlach

C

,

Haferlach

T

.

Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2

.

Haematologica

.

2018

;

103

(

8

):

e348

-

e350

.

28.

Shomali

W

,

Gotlib

J

.

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management

.

Am J Hematol

.

2024

;

99

(

5

):

946

-

968

.

29.

Jovanovic

JV

,

Score

J

,

Waghorn

K

, et al.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

.

Blood

.

2007

;

109

(

11

):

4635

-

4640

.

30.

Walz

C

,

Score

J

,

Mix

J

, et al.

The molecular anatomy of the FIP1L1-PDGFRA fusion gene

.

Leukemia

.

2009

;

23

(

2

):

271

-

278

.

31.

Strati

P

,

Tang

G

,

Duose

DY

, et al.

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

.

Leuk Lymphoma

.

2018

;

59

(

7

):

1672

-

1676

.

32.

Di Giacomo

D

,

Quintini

M

,

Pierini

V

, et al.

Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement

.

Ann Hematol

.

2022

;

101

(

2

):

297

-

307

.

33.

Kluin-Nelemans

HC

,

Reiter

A

,

Illerhaus

A

, et al.

Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

.

Leukemia

.

2020

;

34

(

4

):

1090

-

1101

.

34.

Schwaab

J

,

Umbach

R

,

Metzgeroth

G

, et al.

KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance

.

Am J Hematol

.

2015

;

90

(

9

):

774

-

777

.

35.

Patel

AB

,

Franzini

A

,

Leroy

E

, et al.

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

.

Blood

.

2019

;

134

(

26

):

2388

-

2398

.

36.

Shomali

W

,

Damnernsawad

A

,

Theparee

T

, et al.

A novel activating JAK1 mutation in chronic eosinophilic leukemia

.

Blood Adv

.

2021

;

5

(

18

):

3581

-

3586

.

37.

Lafferty

N

,

Salmon

M

,

Cross

NCP

,

Singer

I

,

Cooney

A

,

Jayaprakash

R

.

Chronic eosinophilic leukaemia associated with JAK2 Exon 13 insertion/deletion mutations

.

Acta Haematol

.

2022

;

145

(

2

):

201

-

206

.

38.

Cross

NCP

,

Hoade

Y

,

Tapper

WJ

, et al.

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

.

Leukemia

.

2019

;

33

(

2

):

415

-

425

.

39.

Groh

M

,

Fenwarth

L

,

Labro

M

, et al.

Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: a nationwide CEREO study

.

Am J Hematol

.

2024

;

99

(

6

):

1108

-

1118

.

40.

Wang

SA

,

Tam

W

,

Tsai

AG

, et al.

Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified

.

Mod Pathol

.

2016

;

29

(

8

):

854

-

864

.

41.

Shomali

W

,

Colucci

P

,

George

TI

, et al.

Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group

.

Leukemia

.

2023

;

37

(

5

):

981

-

987

.

42.

Bidet

A

,

Chollet

C

,

Gardembas

M

, et al.

Molecular monitoring of patients with ETV6-PDGFRB rearrangement: implications for therapeutic adaptation

.

Br J Haematol

.

2018

;

182

(

1

):

148

-

152

.

43.

Gotlib

J

.

Tyrosine kinase inhibitors in the treatment of eosinophilic neoplasms and systemic mastocytosis

.

Hematol Oncol Clin North Am

.

2017

;

31

(

4

):

643

-

661

.

44.

Metzgeroth

G

,

Walz

C

,

Score

J

, et al.

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

.

Leukemia

.

2007

;

21

(

6

):

1183

-

1188

.

45.

Jawhar

M

,

Naumann

N

,

Schwaab

J

, et al.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

.

Ann Hematol

.

2017

;

96

(

9

):

1463

-

1470

.

46.

Pardanani

A

,

Ketterling

RP

,

Li

CY

, et al.

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

.

Leuk Res

.

2006

;

30

(

8

):

965

-

970

.

47.

Baccarani

M

,

Cilloni

D

,

Rondoni

M

, et al.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

.

Haematologica

.

2007

;

92

(

9

):

1173

-

1179

.

48.

Metzgeroth

G

,

Walz

C

,

Erben

P

, et al.

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study

.

Br J Haematol

.

2008

;

143

(

5

):

707

-

715

.

49.

Helbig

G

,

Moskwa

A

,

Hus

M

, et al.

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

.

Cancer Chemother Pharmacol

.

2011

;

67

(

4

):

967

-

969

.

50.

Pardanani

A

,

D'Souza

A

,

Knudson

RA

,

Hanson

CA

,

Ketterling

RP

,

Tefferi

A

.

Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome

.

Leukemia

.

2012

;

26

(

11

):

2439

-

2441

.

51.

Legrand

F

,

Renneville

A

,

MacIntyre

E

, et al.

The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases

.

Medicine (Baltim)

.

2013

;

92

(

5

):

e1

-

e9

.

52.

Metzgeroth

G

,

Schwaab

J

,

Naumann

N

, et al.

Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

.

Blood Adv

.

2020

;

4

(

3

):

440

-

443

.

53.

Klion

AD

,

Robyn

J

,

Akin

C

, et al.

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

.

Blood

.

2004

;

103

(

2

):

473

-

478

.

54.

Helbig

G

,

Stella-Hołowiecka

B

,

Majewski

M

, et al.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients

.

Br J Haematol

.

2008

;

141

(

2

):

200

-

204

.

55.

Helbig

G

,

Moskwa

A

,

Swiderska

A

, et al.

Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up

.

Br J Haematol

.

2009

;

145

(

1

):

132

-

134

.

56.

Lierman

E

,

Folens

C

,

Stover

EH

, et al.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

.

Blood

.

2006

;

108

(

4

):

1374

-

1376

.

57.

Lierman

E

,

Michaux

L

,

Beullens

E

, et al.

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib

.

Leukemia

.

2009

;

23

(

5

):

845

-

851

.

58.

Lierman

E

,

Smits

S

,

Appleby

N

,

Conneally

E

,

Michaux

L

,

Vandenberghe

P

.

FIP1L1-PDGFRα p.T674I-D842L: a novel and ponatinib resistant compound mutation in FIP1L1-PDGFRα positive leukemia

.

Hemasphere

.

2019

;

3

(

2

):

e182

.

59.

Metzgeroth

G

,

Erben

P

,

Martin

H

, et al.

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

.

Leukemia

.

2012

;

26

(

1

):

162

-

164

.

60.

Al-Riyami

AZ

,

Hudoba

M

,

Young

S

,

Forrest

D

.

Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia

.

Leuk Lymphoma

.

2013

;

54

(

8

):

1788

-

1790

.

61.

Heinrich

MC

,

Jones

RL

,

von Mehren

M

, et al.

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

.

Lancet Oncol

.

2020

;

21

(

7

):

935

-

946

.

62.

Klion

AD

,

Robyn

J

,

Maric

I

, et al.

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

.

Blood

.

2007

;

110

(

10

):

3552

-

3556

.

63.

Qu

SQ

,

Qin

TJ

,

Xu

ZF

, et al.

Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China

.

Oncotarget

.

2016

;

7

(

22

):

33229

-

33236

.

64.

Helbig

G

,

Soja

A

,

Świderska

A

,

Hus

M

,

Kyrcz-Krzemień

S

.

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript

.

Leuk Lymphoma

.

2016

;

57

(

3

):

708

-

710

.

65.

Jawhar

M

,

Naumann

N

,

Knut

M

, et al.

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

.

Leukemia

.

2017

;

31

(

10

):

2271

-

2273

.

66.

Singh

ZN

,

Richards

S

,

El Chaer

F

, et al.

Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm

.

Leuk Lymphoma

.

2019

;

60

(

5

):

1304

-

1307

.

67.

Zimmermann

N

,

Nassiri

M

,

Zhou

J

,

Miller

AM

,

Zhang

S

.

Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing

.

Cancer Genet

.

2020

;

244

:

55

-

59

.

68.

Berking

AC

,

Flaadt

T

,

Behrens

YL

, et al.

Rare and potentially fatal - cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children

.

Cancer Genet

.

2023

;

272-273

:

29

-

34

.

69.

Qu

S

,

Yan

Y

,

Li

C

, et al.

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy

.

Leuk Res Rep

.

2023

;

19

:

100367

.

70.

De Luca-Johnson

J

,

Ninfea

JI

,

Pearson

L

, et al.

Myeloid neoplasms with t(5;12) and ETV6-ACSL6 gene fusion, potential mimickers of myeloid neoplasm with PDGFRB rearrangement: case report with imatinib therapy and review of the literature

.

Case Rep Med

.

2016

;

2016

:

8324791

.

71.

Su

Z

,

Liu

X

,

Hu

W

, et al.

Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features

.

Hematology

.

2022

;

27

(

1

):

1010

-

1018

.

72.

Zhao

C

,

Wang

M

,

Zhan

Y

, et al.

A novel IL3-ETV6 fusion in chronic eosinophilic leukemia not otherwise specified with t(5; 12) (q31; p13): a case report and literature review

.

Front Oncol

.

2022

;

12

:

887945

.

73.

Cheah

CY

,

Burbury

K

,

Apperley

JF

, et al.

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

.

Blood

.

2014

;

123

(

23

):

3574

-

3577

.

74.

David

M

,

Cross

NC

,

Burgstaller

S

, et al.

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders

.

Blood

.

2007

;

109

(

1

):

61

-

64

.

75.

Apperley

JF

,

Gardembas

M

,

Melo

JV

, et al.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

.

N Engl J Med

.

2002

;

347

(

7

):

481

-

487

.

76.

Arefi

M

,

García

JL

,

Peñarrubia

MJ

, et al.

Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement

.

Eur J Haematol

.

2012

;

89

(

1

):

37

-

41

.

77.

Zhang

Y

,

Gao

Y

,

Zhang

H

, et al.

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia

.

Blood

.

2018

;

131

(

20

):

2256

-

2261

.

78.

Macdonald

D

,

Aguiar

RC

,

Mason

PJ

,

Goldman

JM

,

Cross

NC

.

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review

.

Leukemia

.

1995

;

9

(

10

):

1628

-

1630

.

79.

Inhorn

RC

,

Aster

JC

,

Roach

SA

, et al.

A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity

.

Blood

.

1995

;

85

(

7

):

1881

-

1887

.

80.

Li

T

,

Zhang

G

,

Zhang

X

,

Lin

H

,

Liu

Q

.

The 8p11 myeloproliferative syndrome: genotypic and phenotypic classification and targeted therapy

.

Front Oncol

.

2022

;

12

:

1015792

.

81.

Umino

K

,

Fujiwara

SI

,

Ikeda

T

, et al.

Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement

.

Hematology

.

2018

;

23

(

8

):

470

-

477

.

82.

Chen

J

,

Deangelo

DJ

,

Kutok

JL

, et al.

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

.

Proc Natl Acad Sci U S A

.

2004

;

101

(

40

):

14479

-

14484

.

83.

Chase

A

,

Bryant

C

,

Score

J

,

Cross

NCP

.

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

.

Haematologica

.

2013

;

98

(

1

):

103

-

106

.

84.

Landberg

N

,

Dreimane

A

,

Rissler

M

,

Billström

R

,

Ågerstam

H

.

Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib

.

Eur J Haematol

.

2017

;

99

(

5

):

442

-

448

.

85.

Wehrli

M

,

Oppliger Leibundgut

E

,

Gattiker

HH

,

Manz

MG

,

Müller

AMS

,

Goede

JS

.

Response to tyrosine kinase inhibitors in myeloproliferative neoplasia with 8p11 translocation and CEP110-FGFR1 rearrangement

.

Oncol

.

2017

;

22

(

4

):

480

-

483

.

86.

Kreil

S

,

Ades

L

,

Bommer

M

, et al.

Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes [abstract]

.

Blood

.

2015

;

126

(

23

):

2812

.

87.

Kasbekar

M

,

Nardi

V

,

Dal Cin

P

, et al.

Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

.

Blood Adv

.

2020

;

4

(

13

):

3136

-

3140

.

88.

Reiter

A

,

Walz

C

,

Watmore

A

, et al.

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

.

Cancer Res

.

2005

;

65

(

7

):

2662

-

2667

.

89.

Schwaab

J

,

Naumann

N

,

Luebke

J

, et al.

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes

.

Am J Hematol

.

2020

;

95

(

7

):

824

-

833

.

90.

Rumi

E

,

Milosevic

JD

,

Casetti

I

, et al.

Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene

.

J Clin Oncol

.

2013

;

31

(

17

):

e269

-

e271

.

91.

Rumi

E

,

Milosevic

JD

,

Selleslag

D

, et al.

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene

.

Ann Hematol

.

2015

;

94

(

11

):

1927

-

1928

.

92.

Kaplan

HG

,

Jin

R

,

Bifulco

CB

,

Scanlan

JM

,

Corwin

DR

.

PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia: a systematic review of the clinical literature

.

Oncol

.

2022

;

27

(

8

):

e661

-

e670

.

93.

Walz

C

,

Erben

P

,

Ritter

M

, et al.

Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

.

Blood

.

2011

;

118

(

8

):

2239

-

2242

.

94.

Tang

G

,

Tam

W

,

Short

NJ

, et al.

Myeloid/lymphoid neoplasms with FLT3 rearrangement

.

Mod Pathol

.

2021

;

34

(

9

):

1673

-

1685

.

95.

Falchi

L

,

Mehrotra

M

,

Newberry

KJ

, et al.

ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant

.

Leukemia

.

2014

;

28

(

10

):

2090

-

2092

.

96.

Venable

ER

,

Gagnon

MF

,

Pitel

BA

, et al.

A TRIP11:: FLT3 gene fusion in a patient with myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions: a case report and review of the literature

.

Cold Spring Harb Mol Case Stud

.

2023

;

9

(

1

):

a006243

.

97.

Zaliova

M

,

Moorman

AV

,

Cazzaniga

G

, et al.

Characterization of leukemias with ETV6-ABL1 fusion

.

Haematologica

.

2016

;

101

(

9

):

1082

-

1093

.

98.

Pardanani

A

,

Brockman

SR

,

Paternoster

SF

, et al.

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

.

Blood

.

2004

;

104

(

10

):

3038

-

3045

.

99.

Chen

M

,

Wang

K

,

Cai

X

, et al.

Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: an analysis of 16 cases show common features and poor prognosis

.

Hematology

.

2021

;

26

(

1

):

153

-

159

.

100.

Shao

H

,

Wang

W

,

Song

J

, et al.

Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement

.

Leuk Res

.

2020

;

99

:

106460

.